174 related articles for article (PubMed ID: 32703496)
21. Prognostic impact of ATM mutations in patients with metastatic colorectal cancer.
Randon G; Fucà G; Rossini D; Raimondi A; Pagani F; Perrone F; Tamborini E; Busico A; Peverelli G; Morano F; Niger M; Antista M; Corallo S; Saggio S; Borelli B; Zucchelli G; Milione M; Pruneri G; Di Bartolomeo M; Falcone A; de Braud F; Cremolini C; Pietrantonio F
Sci Rep; 2019 Feb; 9(1):2858. PubMed ID: 30814645
[TBL] [Abstract][Full Text] [Related]
22. An miRNA signature associated with tumor mutation burden in endometrial cancer.
Zhou H; Chen L; Qin M; Lei Y; Li T; Li H; Cheng X
Biosci Rep; 2020 Nov; 40(11):. PubMed ID: 33141168
[TBL] [Abstract][Full Text] [Related]
23. Immune checkpoint expression, microsatellite instability, and mutational burden: Identifying immune biomarker phenotypes in uterine cancer.
Jones NL; Xiu J; Rocconi RP; Herzog TJ; Winer IS
Gynecol Oncol; 2020 Feb; 156(2):393-399. PubMed ID: 31882243
[TBL] [Abstract][Full Text] [Related]
24. Exploration of a novel prognostic risk signatures and immune checkpoint molecules in endometrial carcinoma microenvironment.
Liu J; Nie S; Wu Z; Jiang Y; Wan Y; Li S; Meng H; Zhou S; Cheng W
Genomics; 2020 Sep; 112(5):3117-3134. PubMed ID: 32474122
[TBL] [Abstract][Full Text] [Related]
25. MUC16 mutations improve patients' prognosis by enhancing the infiltration and antitumor immunity of cytotoxic T lymphocytes in the endometrial cancer microenvironment.
Hu J; Sun J
Oncoimmunology; 2018; 7(10):e1487914. PubMed ID: 30288353
[TBL] [Abstract][Full Text] [Related]
26. Alteration in TET1 as potential biomarker for immune checkpoint blockade in multiple cancers.
Wu HX; Chen YX; Wang ZX; Zhao Q; He MM; Wang YN; Wang F; Xu RH
J Immunother Cancer; 2019 Oct; 7(1):264. PubMed ID: 31623662
[TBL] [Abstract][Full Text] [Related]
27. Association between pathogenic germline mutations in BRCA2 and ATM and tumor-infiltrating lymphocytes in primary prostate cancer.
Kaur HB; Vidotto T; Mendes AA; Salles DC; Isaacs WB; Antonarakis ES; Lotan TL
Cancer Immunol Immunother; 2022 Apr; 71(4):943-951. PubMed ID: 34533610
[TBL] [Abstract][Full Text] [Related]
28. ATM may be a protective factor in endometrial carcinogenesis with the progesterone pathway.
Shan W; Wang C; Zhang Z; Luo X; Ning C; Yu Y; Feng Y; Gu C; Chen X
Tumour Biol; 2015 Mar; 36(3):1529-37. PubMed ID: 25608836
[TBL] [Abstract][Full Text] [Related]
29. POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer.
van Gool IC; Eggink FA; Freeman-Mills L; Stelloo E; Marchi E; de Bruyn M; Palles C; Nout RA; de Kroon CD; Osse EM; Klenerman P; Creutzberg CL; Tomlinson IP; Smit VT; Nijman HW; Bosse T; Church DN
Clin Cancer Res; 2015 Jul; 21(14):3347-3355. PubMed ID: 25878334
[TBL] [Abstract][Full Text] [Related]
30. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
Manzano RG; Catalan-Latorre A; Brugarolas A
BMC Cancer; 2021 Apr; 21(1):432. PubMed ID: 33879103
[TBL] [Abstract][Full Text] [Related]
31. Development of an immune gene prognostic classifier for survival prediction and respond to immunocheckpoint inhibitor therapy/chemotherapy in endometrial cancer.
Liu J; Chen X; Jiang Y; Cheng W
Int Immunopharmacol; 2020 Sep; 86():106735. PubMed ID: 32619957
[TBL] [Abstract][Full Text] [Related]
32. Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide.
Antonarakis ES; Lu C; Luber B; Liang C; Wang H; Chen Y; Silberstein JL; Piana D; Lai Z; Chen Y; Isaacs WB; Luo J
Eur Urol; 2018 Aug; 74(2):218-225. PubMed ID: 29439820
[TBL] [Abstract][Full Text] [Related]
33. PD-L1 and CD4 are independent prognostic factors for overall survival in endometrial carcinomas.
Zhang S; Minaguchi T; Xu C; Qi N; Itagaki H; Shikama A; Tasaka N; Akiyama A; Sakurai M; Ochi H; Satoh T
BMC Cancer; 2020 Feb; 20(1):127. PubMed ID: 32066405
[TBL] [Abstract][Full Text] [Related]
34. Identification of prognostic immune-related genes in the tumor microenvironment of endometrial cancer.
Chen P; Yang Y; Zhang Y; Jiang S; Li X; Wan J
Aging (Albany NY); 2020 Feb; 12(4):3371-3387. PubMed ID: 32074080
[TBL] [Abstract][Full Text] [Related]
35. Prognostic value and immunological role of PDCD1 gene in pan-cancer.
Miao Y; Wang J; Li Q; Quan W; Wang Y; Li C; Wu J; Mi D
Int Immunopharmacol; 2020 Dec; 89(Pt B):107080. PubMed ID: 33069926
[TBL] [Abstract][Full Text] [Related]
36. Low mutation and neoantigen burden and fewer effector tumor infiltrating lymphocytes correlate with breast cancer metastasization to lymph nodes.
Wang Z; Liu W; Chen C; Yang X; Luo Y; Zhang B
Sci Rep; 2019 Jan; 9(1):253. PubMed ID: 30670769
[TBL] [Abstract][Full Text] [Related]
37. Multi-omics profiling reveals distinct microenvironment characterization of endometrial cancer.
Cai Y; Chang Y; Liu Y
Biomed Pharmacother; 2019 Oct; 118():109244. PubMed ID: 31352239
[TBL] [Abstract][Full Text] [Related]
38. ATM Mutations Benefit Bladder Cancer Patients Treated With Immune Checkpoint Inhibitors by Acting on the Tumor Immune Microenvironment.
Yi R; Lin A; Cao M; Xu A; Luo P; Zhang J
Front Genet; 2020; 11():933. PubMed ID: 32922441
[TBL] [Abstract][Full Text] [Related]
39. Prognostic significance of immune landscape in tumour microenvironment of endometrial cancer.
Li BL; Wan XP
J Cell Mol Med; 2020 Jul; 24(14):7767-7777. PubMed ID: 32424934
[TBL] [Abstract][Full Text] [Related]
40. Lower ataxia telangiectasia mutated (ATM) mRNA expression is correlated with poor outcome of laryngeal and pharyngeal cancer patients.
Lee KW; Tsai YS; Chiang FY; Huang JL; Ho KY; Yang YH; Kuo WR; Chen MK; Lin CS
Ann Oncol; 2011 May; 22(5):1088-1093. PubMed ID: 21127011
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
